MELBOURNE, Australia and INDIANAPOLIS, United States, March 16, 2026
Telix Pharmaceuticals has announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TLX101-Px (Pixclara®), an investigational PET imaging agent designed to detect recurrent or progressive glioma, one of the most aggressive forms of brain cancer. The resubmission follows the company’s submission of additional clinical data and statistical analyses requested by the FDA, addressing issues raised in a prior Complete Response Letter. Telix believes the updated dataset strengthens the regulatory application and supports the potential approval of a novel imaging technology capable of improving diagnosis and treatment management for both adult and pediatric brain cancer patients.
Innovative PET Imaging Technology for Glioma Detection
TLX101-Px (Floretyrosine F18 or 18F-FET) is an advanced positron emission tomography (PET) imaging agent designed to help clinicians distinguish between tumor recurrence and treatment-related changes in patients with glioma, a major diagnostic challenge in neuro-oncology. Gliomas are highly infiltrative tumors originating from glial cells within the brain, and they represent approximately 30% of all central nervous system tumors and about 80% of malignant brain cancers.
Traditional imaging methods often struggle to accurately differentiate between tumor progression and post-treatment effects such as radiation-induced inflammation, which can lead to delayed or inappropriate treatment decisions. TLX101-Px targets L-type amino acid transport proteins (LAT1 and LAT2), which are highly expressed in many cancer cells. By binding to these proteins, the imaging agent enables more precise visualization of tumor metabolism and activity, providing clinicians with a powerful diagnostic tool for monitoring disease progression.
Importantly, PET imaging with 18F-FET is already recommended in international clinical guidelines for glioma imaging, highlighting its recognized value within the global neuro-oncology community. However, despite widespread clinical interest, there is currently no FDA-approved targeted amino acid PET imaging agent for brain cancer available in the United States, creating a significant unmet need in diagnostic imaging.
Advertisement
FDA Designations Highlight Unmet Medical Need
Recognizing the potential clinical value of TLX101-Px, the FDA has granted both Orphan Drug Designation and Fast Track Designation to the investigational imaging agent. These regulatory pathways are designed to accelerate development and review of therapies addressing rare diseases or serious medical conditions with limited treatment options.
Glioblastoma (GBM), the most aggressive form of glioma, affects approximately 22,000 patients in the United States each year and is associated with extremely poor prognosis. Even with aggressive treatment—including surgery, radiation therapy, and chemotherapy—tumor recurrence occurs in nearly all patients, with an average survival time of 12 to 15 months following diagnosis. Because recurrence is almost inevitable, accurate imaging tools that allow clinicians to detect disease progression earlier are critically important for guiding treatment strategies.
By enabling physicians to more accurately identify active tumor tissue, TLX101-Px may significantly improve patient management in the post-treatment setting. The imaging agent could also help clinicians determine which patients may benefit from additional therapies or enrollment in clinical trials, improving overall treatment outcomes for individuals living with aggressive brain tumors.
Supporting Future Precision Oncology Strategies
In addition to its diagnostic value, TLX101-Px may play a key role in future precision oncology strategies, particularly as a potential companion diagnostic agent for Telix’s therapeutic candidate TLX101-Tx (iodofalan 131I). This investigational therapy targets the same LAT1 amino acid transport pathway, allowing researchers to potentially pair diagnostic imaging with targeted treatment in a theranostic approach to brain cancer management.
Theranostics—combining diagnostic imaging with targeted radiopharmaceutical therapies—is emerging as one of the most promising fields in oncology. By identifying tumors that express specific molecular targets, physicians can select patients most likely to respond to targeted treatments, improving both safety and therapeutic effectiveness.
Telix’s NDA resubmission represents a crucial regulatory step toward bringing this technology to the United States. If approved, TLX101-Px could become the first targeted amino acid PET imaging agent for brain cancer diagnosis available to clinicians in the U.S., potentially transforming the way gliomas are diagnosed and monitored.
As the global burden of brain cancer continues to grow, innovations in molecular imaging are becoming increasingly important in advancing precision medicine. The successful approval of TLX101-Px could therefore represent a major milestone in neuro-oncology diagnostics, enabling clinicians to make more informed treatment decisions and improve outcomes for patients facing one of the most challenging forms of cancer.
Source: Telix press release
